NCT04339400View on ClinicalTrials.gov

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

PHASE1UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

June 30, 2021

Conditions
Myeloproliferative Neoplasms
Interventions
DRUG

TQ05105

TQ05105 is a JAK2 inhibitor.

Trial Locations (2)

300020

RECRUITING

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

610041

RECRUITING

West China Hospital ,Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY